EAM Investors’s Nurix Therapeutics NRIX Stock Holding History

EAM Investors’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-174,760	Closed	-$3.93M	–	323
2024 Q3	$3.93M	Buy	174,760 +683	+0.4%	+$15.5K	0.59%	79
2024 Q2	$3.63M	Buy	+174,077	New	+$2.71M	0.59%	81
2020 Q4	–	Sell	-35,210	Closed	-$1.23M	–	360
2020 Q3	$1.23M	Buy	+35,210	New	+$887K	0.29%	154

Other funds holding NRIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM Investors's NRIX Position: Q4 2024 in Review

EAM Investors sold out of Nurix Therapeutics (NRIX) in Q4 2024, closing a stake of 174,760 shares — an estimated $3.93M sold.

EAM Investors first reported a position in NRIX in Q3 2020 and held it in 3 quarters. The position peaked at $3.93M in Q3 2024. 175 funds tracked by Wall St. Rank hold NRIX as of Q4 2024.

EAM Investors reported no remaining Nurix Therapeutics position as of Q4 2024 after selling out during the quarter.
EAM Investors sold 174,760 Nurix Therapeutics shares in Q4 2024, an estimated $3.93M.
EAM Investors first reported a position in Nurix Therapeutics in Q3 2020 and held it in 3 quarters.
EAM Investors's Nurix Therapeutics position peaked at $3.93M in Q3 2024.
175 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2024.

Based on EAM Investors's 13F filing for Q4 2024, filed 13 Feb 2025.